Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MajesTEC-4 maintenance therapy study in newly diagnosed multiple myeloma after autologous stem cell transplantation
2023-510384-36-00Phase 3Authorised
- Sponsor
- European Myeloma Network
- Start
- Sep 2022
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 25
01
Overview
Phase 3 trial of teclistamab and lenalidomide, sponsored by European Myeloma Network. Planned start Sep 2022; status: authorised.
02
Drugs
teclistamablenalidomide
Beyond the preview
Go deeper on 2023-510384-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510384-36-00.